Clinical and Molecular Hepatology

"Sang Jung Park"

Original Articles

Liver fibrosis, cirrhosis, and portal hypertension

Cyanoacrylate injection versus band ligation for bleeding from cardiac varices along the lesser curvature of the stomach: Sang Jung Park, Yong Kwon Kim, Yeon Seok Seo, Seung Woon Park, Han Ah Lee, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jae Young Jang, Jong Eun Yeon, Kwan Soo Byun; Clin Mol Hepatol 2016;22(4):487-494.
Published online December 25, 2016; DOI: https://doi.org/10.3350/cmh.2016.0050

Abstract
PDF

Background/Aims
Practice guidelines recommend endoscopic band ligation (EBL) and endoscopic variceal obturation (EVO) for bleeding from esophageal varices and fundal varices, respectively. However, the optimal treatment for bleeding from cardiac varices along the lesser curvature of the stomach (GOV1) remains undefined. This retrospective study compared the efficacy between EBL and EVO for bleeding from GOV1.
Methods
Patients treated by EBL or EVO via cyanoacrylate injection for bleeding from GOV1 were enrolled. Patients diagnosed with hepatocellular carcinoma or treated with endoscopic injection sclerotherapy were excluded.
Result
s: The study included 91 patients treated for bleeding from GOV1. The mean age was 56.3±10.9 years (mean±SD), and 78 of them (85.7%) were men. Overall, 51 and 40 patients were treated with EBL and EVO, respectively. A trend for a higher hemostasis rate was noted in the EVO group (100%) than in the EBL group (82.6%, P=0.078). Varices rebled in 15 patients during follow-up. The rebleeding rate was significantly higher in the EBL group than in the EVO group (P=0.004). During follow-up, 13 patients died (11 in the EBL group and 2 in the EVO group); the survival rate was marginally significant between two groups (P=0.050). The rebleeding-free survival rate was significantly higher in the EVO group than in the EBL group (P=0.001).
Conclusions
Compared to EBL, EVO offered significantly lower rebleeding rates, significantly higher rebleeding-free survival rates, and a trend for higher hemostasis and survival rates. EVO appears to be the better therapeutic option for bleeding from GOV1.

Citations

Citations to this article as recorded by

Endoscopic management of acute esophagogastric variceal bleeding: recent advances
Xinhui Li, Jing Wang, Qun Li, Wenbo Li, Xingshun Qi, Xiaofeng Liu
Therapeutic Advances in Gastroenterology.2026;[Epub] CrossRef
Short-term efficacy and safety of endoscopic injection of low dose of sclerotherapy and cyanoacrylate injection for type GOV1 gastric varices combined with endoscopic variceal ligation for esophageal varices
Tingting Zhang, Chuangyang Xin, Xueyun Guo, Sihai Chen, Xuelian Zheng, Wen Xu, Dongjing Zhang, Biming Li, Ye Chen, Xuan Zhu, Anjiang Wang
Surgical Endoscopy.2025; 39(1): 280. CrossRef
Emergency Plug-Assisted Retrograde Transvenous Obliteration for Active Bleeding from Ruptured Gastric Varices
Eunbyeol Ko, Jeongyeon Kim, Dong Il Gwon, Hee Ho Chu, Gun Ha Kim, Gi-Young Ko
Journal of Vascular and Interventional Radiology.2025; 36(6): 994. CrossRef
A randomized controlled trial comparing large-volume band ligator and cyanoacrylate injection in the endoscopic management of actively bleeding gastric varices
Ding Shi, Guojing Xu, Weijin Pan
Scientific Reports.2025;[Epub] CrossRef
Evaluation of the efficacy and safety of endoscopic band ligation in the treatment of bleeding from mild to moderate gastric varices type 1
Yue Deng, Ya Jiang, Tong Jiang, Ling Chen, Hai-Jun Mou, Bi-Guang Tuo, Guo-Qing Shi
World Journal of Gastroenterology.2024; 30(5): 440. CrossRef
Gastric variceal obstruction improves the efficacy of endoscopic management of esophageal variceal bleeding in GOV type I
Xiaoquan Huang, Detong Zou, Huishan Wang, Wei Chen, Lili Zhang, Feng Li, Lili Ma, Chunqing Zhang, Ying Chen, Shiyao Chen
Endoscopy International Open.2024; 12(08): E940. CrossRef
Aluminum phosphate gel reduces early rebleeding in cirrhotic patients with gastric variceal bleeding treated with histoacryl injection therapy
Hao-Tian Zeng, Zhu-Liang Zhang, Xi-Min Lin, Min-Si Peng, Li-Sheng Wang, Zheng-Lei Xu
World Journal of Gastrointestinal Endoscopy.2023; 15(3): 153. CrossRef
A case report of an endoscopic approach to life‐threatening cecal variceal hemorrhage
Kirsty E MacFarlane, Nicholas J Fischer
JGH Open.2022; 6(4): 277. CrossRef
Endoscopic variceal obturation and retrograde transvenous obliteration for acute gastric cardiofundal variceal bleeding in liver cirrhosis
Han Ah Lee, Jungwon Kwak, Sung Bum Cho, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Seung Up Kim, Hyonggin An, Hyung Joon Yim, Jong Eun Yeon, Yeon Seok Seo
BMC Gastroenterology.2022;[Epub] CrossRef
Diagnosis and Management of Esophageal and Gastric Variceal Bleeding: Focused on 2019 KASL Clinical Practice Guidelines for Liver Cirrhosis
Min Kyung Park, Yun Bin Lee
The Korean Journal of Gastroenterology.2021; 78(3): 152. CrossRef
Endoscopic Removal of Inflated Transected Sengstaken–Blakemore Tube Using Endoscopic Scissors
Jun Ho Lee, Eu-Kwon Hwang, Chanmesa Doeun, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
Clinical Endoscopy.2019; 52(2): 182. CrossRef
Prevention and management of gastroesophageal varices
Yeon Seok Seo
Clinical and Molecular Hepatology.2018; 24(1): 20. CrossRef
The Choice of Interventional Treatment of Gastric Variceal Hemorrhage: What Is Better?
Moon Young Kim
Gut and Liver.2018; 12(6): 611. CrossRef
Endoscopic Therapy for Variceal Bleeding: from Patient Preparation to Available Techniques and Rescue Therapies
Philippe Sultanik, Dominique Thabut
Current Hepatology Reports.2017; 16(4): 398. CrossRef

12,872 View
158 Download
15 Web of Science
Crossref

Viral hepatitis

Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B: Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um; Clin Mol Hepatol 2016;22(3):382-389.
Published online September 25, 2016; DOI: https://doi.org/10.3350/cmh.2016.0047

Abstract
PDF

Background/Aims
Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment response. This study aimed to determine the relationship between the HBsAg titer and the entecavir (ETV) off-treatment response.
Methods
This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years, mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; HBV DNA level, 6.8±1.3 log10 IU/mL) treated with ETV for a sufficient duration and in whom treatment was discontinued after HBsAg levels were measured. A virological relapse was defined as an increase in serum HBV DNA level of >2000 IU/mL, and a clinical relapse was defined as a virological relapse with a biochemical flare, defined as an increase in the serum alanine aminotransferase level of >2 × upper limit of normal.
Result
s: After stopping ETV, virological relapse and clinical relapse were observed in 32 and 24 patients, respectively, during 20.8±19.9 months of follow-up. The cumulative incidence rates of virological relapse were 36.2% and 66.2%, respectively, at 6 and 12 months, and those of clinical relapse were 14.3% and 42.3%. The off-treatment HBsAg level was an independent factor associated with clinical relapse (hazard ratio, 2.251; 95% confidence interval, 1.076–4.706; P=0.031). When patients were grouped according to off-treatment HBsAg levels, clinical relapse did not occur in patients with an off-treatment HBsAg level of ≤2 log₁₀ IU/mL (n=5), while the incidence rates of clinical relapse at 12 months after off-treatment were 28.4% and 55.7% in patients with off-treatment HBsAg levels of >2 and ≤3 log₁₀ IU/mL (n=11) and >3 log₁₀ IU/mL (n=28), respectively.
Conclusions
The off-treatment HBsAg level is closely related to clinical relapse after treatment cessation. A serum HBsAg level of <2 log₁₀ IU/mL is an excellent predictor of a sustained off-treatment response in CHB patients who have received ETV for a sufficient duration.

Citations

Citations to this article as recorded by

Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries
Ben Kang, Dae Yong Yi, Byung-Ho Choe
Frontiers in Pediatrics.2022;[Epub] CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2022; 28(2): 276. CrossRef
Drug Discovery Study Aimed at a Functional Cure for HBV
Takehisa Watanabe, Sanae Hayashi, Yasuhito Tanaka
Viruses.2022; 14(7): 1393. CrossRef
Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile
Sheng-Jie Shiue, Chao-Ling Cheng, Han-Shiang Shiue, Chun-Nan Chen, Sheng-Wei Cheng, Li-Wei Wu, Ganbolor Jargalsaikhan, Tze-Sian Chan, Hsin-Yi Lin, Ming-Shun Wu
Nutrients.2022; 14(14): 2790. CrossRef
Long‐term clinical outcome of HBeAg‐negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues
Spilios Manolakopoulos, Hariklia Kranidioti, Anastasia Kourikou, Melanie‐Maria Deutsch, Christos Triantos, Chrysostomos Tsolias, Emanuel K. Manesis, Nicoletta Mathou, Alexandra Alexopoulou, Emilia Hadziyannis, George Papatheodoridis
Liver International.2021; 41(1): 48. CrossRef
Advances in treatment and prevention of hepatitis B
Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav
World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56. CrossRef
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis
Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson
Gut.2021; : gutjnl-2020-323979. CrossRef
Advances in treatment and prevention of hepatitis B
Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav
World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56. CrossRef
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
Florian van Bömmel, Thomas Berg
Hepatology Communications.2021; 5(10): 1632. CrossRef
Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B
Do Seon Song, Jeong Won Jang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Clinical Infectious Diseases.2021; 73(4): e892. CrossRef
Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
Margarita Papatheodoridi, George Papatheodoridis
Cells.2020; 9(2): 493. CrossRef
The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
Samuel Hall, Jessica Howell, Kumar Visvanathan, Alexander Thompson
Viruses.2020; 12(9): 934. CrossRef
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clinical and Molecular Hepatology.2020; 26(4): 411. CrossRef
Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
Weiqiang Gan, Jianguo Li, Chunlan Zhang, Xuefu Chen, Chaoshuang Lin, Zhiliang Gao
BMC Infectious Diseases.2020;[Epub] CrossRef
Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg‐negative chronic hepatitis B
Hariklia Kranidioti, Spilios Manolakopoulos, George Kontos, Michael S. Breen, Anastasia Kourikou, Melanie Deutsch, Maria Ester Quesada‐Del‐Bosque, Rocio T. Martinez‐Nunez, Mohammed M. Naiyer, Christopher H. Woelk, Tilman Sanchez‐Elsner, Emilia Hadziyannis
Journal of Viral Hepatitis.2019; 26(6): 697. CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef
New Biomarkers of Chronic Hepatitis B
Lung-Yi Mak, Wai-Kay Seto, James Fung, Man-Fung Yuen
Gut and Liver.2019; 13(6): 589. CrossRef
Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B
Florian van Bömmel, Thomas Berg
Liver International.2018; 38(S1): 90. CrossRef
An expert consensus for the management of chronic hepatitis B in Asian Americans
M. J. Tong, C. Q. Pan, S.‐H. B. Han, D. S.‐K. Lu, S. Raman, K.‐Q. Hu, J. K. Lim, H. W. Hann, A. D. Min
Alimentary Pharmacology & Therapeutics.2018; 47(8): 1181. CrossRef

15,555 View
209 Download
18 Web of Science
Crossref

Case Report

Hepatic neoplasm

Spinal cord injury after conducting transcatheter arterial chemoembolization for costal metastasis of hepatocellular carcinoma: Sang Jung Park, Chang Ha Kim, Jin Dong Kim, Soon Ho Um, Sun Young Yim, Min Ho Seo, Dae In Lee, Jun Hyuk Kang, Bora Keum, Yong Sik Kim; Korean J Hepatol 2012;18(3):316-320.
Published online September 25, 2012; DOI: https://doi.org/10.3350/cmh.2012.18.3.316

Abstract
PDF

Transcatheter arterial chemoembolization (TACE) has been used widely to treat patients with unresectable hepatocellular carcinoma. However, this method can induce various adverse events caused by necrosis of the tumor itself or damage to nontumor tissues. In particular, neurologic side effects such as cerebral infarction and paraplegia, although rare, may cause severe sequelae and permanent disability. Detailed information regarding the treatment process and prognosis associated with this procedure is not yet available. We experienced a case of paraplegia that occurred after conducting TACE through the intercostal artery to treat hepatocellular carcinoma that had metastasized to the rib. In this case, TACE was attempted to relieve severe bone pain, which had persisted even after palliative radiotherapy. A sudden impairment of sensory and motor functions after TACE developed in the trunk below the level of the sternum and in both lower extremities. The patient subsequently received steroid pulse therapy along with supportive care and continuous rehabilitation. At the time of discharge the patient had recovered sufficiently to enable him to walk by himself, although some paresthesia and spasticity remained.

Citations

Citations to this article as recorded by

Spinal Cord Infarction: Clinical and Neuroradiological Clues of a Rare Stroke Subtype
Marialuisa Zedde, Arturo De Falco, Carla Zanferrari, Maria Guarino, Francesca Romana Pezzella, Shalom Haggiag, Gianni Cossu, Rocco Quatrale, Giuseppe Micieli, Massimo Del Sette, Rosario Pascarella
Journal of Clinical Medicine.2025; 14(4): 1293. CrossRef
Spinal cord ischemia after transcatheter artery chemoembolization for hepatocellular carcinoma: A case-report
Le Trung Hieu, Le Van Thanh, Vu Van Quang, Dang Kim Khue, Nguyen Hoang Ngoc Anh, Dao Duc Tien
International Journal of Surgery Case Reports.2023; 106: 108258. CrossRef
Paraplegia following transarterial chemoembolisation for hepatocellular carcinoma: a case report
Gang-Hua Lin, Yu-Lueng Shih
Acta Chirurgica Belgica.2021; 121(6): 437. CrossRef
Selective Versus Non-selective Transarterial Chemoembolization via the Intercostal Artery for the Treatment of Hepatocellular Carcinoma
Dongho Hyun, Sung Ki Cho, Sung Wook Shin, Kwang Bo Park, Hong Suk Park, Sung Wook Choo, Young Soo Do
CardioVascular and Interventional Radiology.2020; 43(4): 587. CrossRef
Paraplegia after transcatheter artery chemoembolization in a child with clear cell sarcoma of the kidney: A case report
Jia-Bin Cai, Min He, Fa-Liang Wang, Jie-Ni Xiong, Jun-Qing Mao, Zhong-Hai Guan, Lin-Jie Li, Jin-Hu Wang
World Journal of Clinical Cases.2020; 8(11): 2332. CrossRef
Doxorubicin/ethiodized oil/gelatin

Reactions Weekly.2014; 1498(1): 13. CrossRef
Spinal Cord Ischemia Secondary to Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
Aziz Bazine, Mohamed Fetohi, Maha Ait Berri, Ismail Essaadi, Kamal Elbakraoui, Mohamed Ichou, Hassan Errihani
Case Reports in Gastroenterology.2014; 8(3): 264. CrossRef